Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Dealbreaker on MSN13h
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal
Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...
Le Lézard15h
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)
Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...
Former Klaviyo employees emerge from stealth with new venture
The former SVP of global sales and the leader in sales engineering from Klaviyo have emerged from stealth with a new startup backed by Klaviyo founders, Asymmetric Capital Partners and Underscore VC.
Zacks Investment Research on MSN20h
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...
Le Lézard9h
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TSVT, BRDG, GB on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...